The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas

Background Galectin-3 (Gal-3) is an anti-apoptotic molecule involved in thyroid cells transformation. It is specifically overexpressed in thyroid tumour cells and is currently used as a preoperative diagnostic marker of thyroid malignancy. Gal-3 expression is downregulated by wt-p53 at the transcriptional level. In well-differentiated thyroid carcinomas (WDTCs) there is an unexplained paradoxical concomitant expression of Gal-3 and wt-p53. HIPK2 is a co-regulator of different transcription factors, and modulates basic cellular processes mainly through the activation of wt-p53. Since we demonstrated that HIPK2 is involved in p53-mediated Gal-3 downregulation, we asked whether HIPK2 deficiency might be responsible for such paradoxical Gal-3 overexpression in WDTC. Methodology/Principal Findings We analyzed HIPK2 protein and mRNA levels, as well as loss of heterozygosity (LOH) at the HIPK2 locus (7q32-34), in thyroid tissue samples. HIPK2 protein levels were high in all follicular hyperplasias (FHs) analyzed. Conversely, HIPK2 was undetectable in 91.7% of papillary thyroid carcinomas (PTCs) and in 60.0% of follicular thyroid carcinomas (FTCs). HIPK2 mRNA levels were upregulated in FH compared to normal thyroid tissue (NTT), while PTC showed mean HIPK2 mRNA levels lower than FH and, in 61.5% of cases, also lower than NTT. We found LOH at HIPK-2 gene locus in 37.5% of PTCs, 14.3% of FTCs and 18.2% of follicular adenomas. To causally link these data with Gal-3 upregulation, we performed in vitro experiments, using the PTC-derived K1 cells, in which HIPK2 expression was manipulated by RNA interference (RNAi) or plasmid-mediated overexpression. HIPK2 RNAi was associated with Gal-3 upregulation, while HIPK2 overexpression with Gal-3 downregulation. Conclusions/Significance Our results indicate that HIPK2 expression and function are impaired in WDTCs, in particular in PTCs, and that this event explains Gal-3 overexpression typically observed in these types of tumours. Therefore, HIPK2 can be considered as a new tumour suppressor gene for thyroid cancers.

[1]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[2]  A. Ballabio,et al.  The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. , 2002, Biochemical and biophysical research communications.

[3]  Y. Arai,et al.  Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription , 2007, Oncogene.

[4]  E. Green,et al.  Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site , 2000, Oncogene.

[5]  K. Huebner,et al.  Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. , 2003, Genomics.

[6]  J. Bartek,et al.  Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies , 1993, The Journal of pathology.

[7]  R. Finley,et al.  Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria , 2002, The Journal of Biological Chemistry.

[8]  A. Schneider,et al.  Long-term risks for thyroid cancer and other neoplasms after exposure to radiation , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[9]  S. Soddu,et al.  Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis , 2006, Molecular and Cellular Biology.

[10]  T. Yoshii,et al.  Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. , 2001, International journal of oncology.

[11]  G. Viglietto,et al.  High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth , 2001, Oncogene.

[12]  A. Raz,et al.  The role of galectin-3 in cancer drug resistance. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  Haojie Huang,et al.  Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer , 1999, Genes, chromosomes & cancer.

[14]  H. Inohara,et al.  Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. , 1997, Cancer Research.

[15]  Giulia Piaggio,et al.  Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.

[16]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[17]  L. Bondeson.  Tumours of the thyroid and parathyroid , 2004 .

[18]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[19]  D. Gudbjartsson,et al.  A high-resolution recombination map of the human genome , 2002, Nature Genetics.

[20]  S. Soddu,et al.  HIPK2: a multitalented partner for transcription factors in DNA damage response and development. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[21]  M. Schmitz,et al.  HIPK2, a Versatile Switchboard Regulating the Transcription Machinery and Cell Death , 2007, Cell cycle.

[22]  Xiaofeng Jiang,et al.  Galectin-3 Targeted Therapy with a Small Molecule Inhibitor Activates Apoptosis and Enhances Both Chemosensitivity and Radiosensitivity in Papillary Thyroid Cancer , 2009, Molecular Cancer Research.

[23]  A. Fusco,et al.  High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. , 2007, The Journal of clinical investigation.

[24]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[25]  M. P. Martegani,et al.  Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. , 2008, The Lancet. Oncology.

[26]  H. Kuwano,et al.  Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. , 2006, Anticancer research.

[27]  David I. Smith,et al.  Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors , 1998, Oncogene.

[28]  Y. Nikiforov.  Is ionizing radiation responsible for the increasing incidence of thyroid cancer? , 2010, Cancer.

[29]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[30]  S. Soddu,et al.  Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas , 2009, The Journal of pathology.

[31]  E. Brunetti,et al.  Frizzled‐1 is down‐regulated in follicular thyroid tumours and modulates growth and invasiveness , 2008, The Journal of pathology.

[32]  S. Natsugoe,et al.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.

[33]  A. Vecchione,et al.  Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. , 2004, Endocrine-related cancer.

[34]  D. Lazzereschi,et al.  Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas , 1998, International journal of cancer.

[35]  M. Emi,et al.  Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q. , 2001, The Journal of clinical endocrinology and metabolism.

[36]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[37]  N. Tinari,et al.  Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Raz.  On the Role of Galectin-3 in Cancer Metastasis : From the Bench to the Clinic and Back , 2008 .

[39]  S. Hirohashi,et al.  Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  A. Schneider,et al.  Thyroid Cancer Following Exposure to Radioactive Iodine , 2000, Reviews in Endocrine and Metabolic Disorders.

[41]  Yoichi Taya,et al.  Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.

[42]  S. Soddu,et al.  HIPKs: Jack of all trades in basic nuclear activities. , 2008, Biochimica et biophysica acta.

[43]  S. Soddu,et al.  HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage , 2009, Cell proliferation.

[44]  M. Papotti,et al.  Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach , 2007, The American journal of surgical pathology.